Ovarian Cancer Trial, Recruiting NCT04284969 Sponsor: Hospices Civils de Lyon Condition: Ovarian Cancer
Back to Ovarian Cancer

Ovarian Cancer Trial, Recruiting

NCT04284969
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Women aged 70 or older, or women aged 60 or older who have significant other health conditions or difficulties with daily activities (confirm with trial site for exact scoring thresholds)
  • People with a confirmed diagnosis of stage III or IV ovarian cancer, primary peritoneal cancer, or fallopian tube cancer, verified by tissue or cell testing
  • People whose care plan includes pelvic surgery, with or without chemotherapy given before the surgery
  • People whose treatment plan has been reviewed and approved by a team of specialist doctors working together
  • People with a life expectancy of more than 3 months
  • People who have given written agreement to take part in the trial
  • People who are covered by a health system where this requirement applies

Who may not be able to join:

  • People who have another active cancer that may affect their outlook or prognosis
  • People whose agreed treatment plan does not include surgery to reduce the tumour
  • People who are unable to attend regular follow-up appointments for any reason, such as location, family situation, social circumstances, or psychological reasons
  • People who are unable to understand and complete the study questionnaires
  • People who are unable to follow the study procedures due to geographic, social, or psychological reasons
  • People who are under legal guardianship or a similar supervised legal arrangement
  • People who are currently detained or imprisoned
  • People who are already taking part in another clinical trial involving an investigational drug
  • People who have already been enrolled in this study previously

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 4.78.86.32.87

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
3 June 2021
Est. completion
3 June 2027

Where this trial is recruiting

🇫🇷 France

Primary endpoints

Superiority for post-treatment complication grade≥3; Superiority of HRQOL on the dimensions

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov